Skip to content
Research Article Open access CC BY 4.0

Analysis of Risk Factors for Mucormycosis in COVID-19 Patients Admitted in Tertiary Care Hospital Aurangabad

M. Naik, Shamisha Khade, Vinayak Bangi, Nilofer Banoisa Patel

Asian Journal of Medicine and Health · pp. 153–160 · Published 19 Oct 2022

10.9734/ajmah/2022/v20i11755

Abstract

Introduction: Mucormycosis manifests as various syndromes in human beings, particularly in immunocompromised patients and those with diabetes mellitus. Recently, several cases of mucormycosis in people with COVID19 have been increasingly reported worldwide, especially from India. This prompted us to conduct a study in mucormycosis patients with COVID-19, to know its clinical profile of the COVID-19 patients with mucormycosis and identify of various risk factors in mucormycosis patients with COVID-19 infection. Materials and Methods: This Cross sectional Retrospective Qualitative Descriptive study was conducted in Department of Medicine, MGM Medical College and Hospital, Aurangabad [Maharashtra]. A total of 100 patients admitted from April 2021 to August 2021 were enrolled as study participants. All COVID-19 patients admitted in MGM who are diagnosed with mucormycosis by microbiologically (KOH mount) or radiologically (CT/MRI) or by histopathology. Observations and Results: The mean age of patients was 59.72±12.47 years. The male 73 (73.0%) predomianance than female 27(27.0%). 88(88.0%) of patients were having Diabetic Mellitus and 31(31.0%) of patients were having hypertension. All the patients were given Antibiotic & steroids during treatment of COVID-19 at hospitalisation. 15(15.0%) of patients were admitted in ICU during treatment of COVID-19. 76(76.0%) patients were required Oxygen, 03(3.0%) were on NIV/Ventilator and 08 (8.0%) patients were on HFOT during treatment of COVID-19. Overall (97.0%) of patients were recovered. Conclusion: Diabetes mellitus is identified as the leading underlying comorbidity in cases diagnosed with mucormycosis in post COVID-19 patients. Also use of steroid, duration of use of steroid, and oxygen therapy during the treatment of COVID-19 were risk factors observed in the patients with mucormycosis.

Mucormycosis steroid in COVID-19 post-COVID-19

References (13)

  1. 1 The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports [DOI]
  2. 2 Epidemiology and Diagnosis of Mucormycosis: An Update [DOI]
  3. 3 Glucocorticoids and invasive fungal infections [DOI]
  4. 4 Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China [DOI]
  5. 5 When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis [DOI]
  6. 6 Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India [DOI]
  7. 7 Mucormycosis: Battle with the Deadly Enemy over a Five-Year Period in India [DOI]
  8. 8 MUCORMYCOSIS—A NEW DISEASE? [DOI]
  9. 9 Mucormycosis in a diabetic patient: A case report with an insight into its pathophysiology [DOI]
  10. 10 A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient [DOI]
  11. 11 Mucormycosis in a Tertiary Care Center in South India: A 4-Year Experience [DOI]
  12. 12 Study of mucormycosis patients attending tertiary care hospital: a retrospective study [DOI]
  13. 13 Invasive fungal rhinosinusitis associated with COVID-19: An observational study [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

62

Page views

0

PDF downloads

14

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.